All Stories

  1. Predictors of Poor Response and Adverse Events Following Botulinum Toxin-A for Refractory Idiopathic Overactive Bladder
  2. How can we better manage drug‐resistant OAB/DO? ICI‐RS 2018
  3. How can we improve the diagnosis and management of bladder pain syndrome? Part 2:ICI‐RS 2018
  4. How can we prevent postprostatectomy urinary incontinence by patient selection, and by preoperative, peroperative, and postoperative measures? International Consultation on Incontinence‐Research Society 2018
  5. Case‐finding tools for the diagnosis of OAB in women: A narrative review
  6. How can we improve the diagnosis and management of bladder pain syndrome? Part 1: ICI‐RS 2018
  7. A national UK audit of suprapubic catheter insertion practice and rate of bowel injury with comparison to a systematic review and meta‐analysis of available research
  8. The MIC-KEY button vesicostomy: a superior alternative for suprapubic drainage?
  9. Female stress urinary incontinence MDT
  10. Onabotulinum toxin A Injections in Men With Refractory Idiopathic Detrusor Overactivity
  11. Feasibility of using a novel non-invasive ambulatory tibial nerve stimulation device for the home-based treatment of overactive bladder symptoms
  12. Nonantibiotic prevention and management of recurrent urinary tract infection
  13. Guideline of guidelines: bladder pain syndrome
  14. What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICI-RS 2017
  15. Re: Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder
  16. The dilemma with comparing efficacy of OAB treatments
  17. Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015)
  18. The role of male slings in post prostatectomy incontinence: ICI-RS 2015
  19. Urethral Sphincter Injection of Botulinum Toxin A: A Review of Its Application and Outcomes
  20. Mixed urinary incontinence- what should we treat first?
  21. Bilateral ureteric obstruction during in vitro fertilisation therapy in a patient with complex surgically managed Crohn's disease
  22. Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder
  23. Getting out of a tight spot: an overview of ureteroenteric anastomotic strictures
  24. Urethral atrophy is fiction! Time to focus on the capsule?
  25. Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014
  26. The Artificial Urinary Sphincter
  27. Persistence with mirabegron therapy for overactive bladder: A real life experience
  28. PDE-5 Inhibitors for BPH-Associated LUTS
  29. The Relationship Between Technical And Nontechnical Skills Within A Simulation-Based Ureteroscopy Training Environment
  30. Integrative review on the non-invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies
  31. Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder
  32. Simulation-Based Ureteroscopy Training: A Systematic Review
  33. Simulation-based ureteroscopy skills training curriculum with integration of technical and non-technical skills: a randomised controlled trial
  34. The changing face of urinary continence surgery in England: a perspective from the Hospital Episode Statistics database
  35. Assessment of treatment-seeking behavior and healthcare utilization in an international cohort of subjects with overactive bladder
  36. Efficacy of flexible ureteroscopy and laser lithotripsy for lower pole renal calculi
  37. Validation of the bladder control self-assessment questionnaire (B-SAQ) in men
  38. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction
  39. What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013
  40. The use of botulinum toxin for the treatment of urologic pain
  41. Is Percutaneous Nephrolithotomy in Solitary Kidneys Safe?
  42. Botulinum toxin-A for overactive bladder: formulations, dosing and clean intermittent catherisation
  43. Botulinum Toxin—What Urologic Uses Does the Data Support?
  44. Current State of the Art in Non-Invasive Urodynamics
  45. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?
  46. Botulinum toxin-A for the treatment of overactive bladder: UK contributions
  47. Recent advances in the diagnosis and treatment of bladder cancer
  48. Overactive bladder and sexual function: a nightmare couple
  49. Bipolar transurethral resection of prostate: Current status in the management of bladder outflow obstruction
  50. Lower Urinary Tract Dysfunction in Multiple Sclerosis
  51. Repeated Botulinum Toxin Type A Injections for Refractory Overactive Bladder: Medium-Term Outcomes, Safety Profile, and Discontinuation Rates
  52. The psychology of LUTS: ICI-RS 2011
  53. Should we inject the trigone during botulinum toxin injection?
  54. Neurogenic Detrusor Overactivity in Patients With Spinal Cord Injury: Evaluation and Management
  55. Testicular pain as a presentation of Cowden syndrome
  56. The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial
  57. Parallel incisions procedure for penile curvature—Short term outcomes
  58. Role of laparoscopic nephrectomy for refractory hypertension in poorly functioning kidneys
  59. Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity
  60. Repeated Injections of Botulinum Toxin-A for Idiopathic Detrusor Overactivity
  61. Re: Eisenberg et al.: Endoscopic Management of Retained Foreign Bodies Following Flexible Ureterorenoscopy for Renal Calculi (Urology 2009;73:1189-1194)
  62. Corrigendum to “Periurethral injections of non-animal stabilised hyaluronic acid/dextranomer gel and sterile abscess formation” [Brit. J. Med. Surg. Urol. 2 (4) (2009) 174–175]
  63. Vesicoureteric reflux diagnosed by urethral catheterisation
  64. Periurethral Non-animal Stabilized Hyaluronic Acid/Dextranomer Injections: Efficacy and Formation of Granuloma/Sterile Abscess
  65. Obstructive jaundice as a presenting symptom of metastatic carcinoma of the prostate
  66. Periurethral injections of non-animal stabilised hyaluronic acid/dextranomer gel and sterile abscess formation
  67. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial
  68. Endovascular management of grade V blunt renal trauma with associated splenic injury
  69. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?
  70. Urodynamic Assessment of Poor Responders After Botulinum Toxin-A Treatment for Overactive Bladder
  71. EFFICACY AND COMPLICATIONS OF INTRADETRUSOR INJECTION WITH BOTULINUM TOXIN A IN PATIENTS WITH REFRACTORY IDIOPATHIC DETRUSOR OVERACTIVITY
  72. Contralateral Recurrence of Testicular Tumor: Which Patients Need Biopsy at Initial Presentation?
  73. Evolution of transdermal oxybutynin in the treatment of overactive bladder
  74. Laparoscopic upper urinary tract surgery for benign and malignant conditions. Does aetiology have an effect on health-related quality of life?*
  75. Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going
  76. BOTULINUM TOXIN A IN THE OVERACTIVE BLADDER: CURRENT STATUS AND FUTURE DIRECTIONS
  77. Efficacy of Botulinum Toxin-A for Treating Idiopathic Detrusor Overactivity: Results From a Single Center, Randomized, Double-Blind, Placebo Controlled Trial
  78. Laparoscopic Nephrectomy in a Patient with Ankylosing Spondylitis: Surgical and Anesthetic Challenges
  79. INFORMED CONSENT: ARE WE DELUDING OURSELVES? A RANDOMIZED CONTROLLED STUDY
  80. Laparoscopic Retroperitoneal Nephrectomy for Giant Hydronephrosis: When Simple Nephrectomy Isn't Simple
  81. Techniques for the intradetrusor administration of botulinum toxin
  82. The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy
  83. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity
  84. Laparoscopic pyeloplasty and pyelopyelostomy for ureteropelvic junction obstruction in a duplicated collecting system
  85. Is botulinum toxin type A a safe and effective treatment for neurogenic urinary incontinence?
  86. Laparoscopic Management of Cryptorchidism in Adults
  87. Laparoscopic ureteroneocystostomy for benign lower ureteric stricture: case study and literature review
  88. Eosinophilic cystitis and its management
  89. Botulinum toxin: A new dimension in the treatment of lower urinary tract dysfunction
  90. Percutaneous versus Open Tendo Achillis Repair
  91. Attitudes of medical and dental students to dissection